Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: A meta-analysis

Alfredo Tartarone, Giandomenico Roviello, Rosa Lerose, Raheleh Roudi, Michele Aieta, Pietro Zoppoli

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.

Original languageEnglish
Pages (from-to)2423-2433
Number of pages11
JournalFuture Oncology
Volume15
Issue number20
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Meta-Analysis
Disease-Free Survival
Therapeutics
Survival

Keywords

  • atezolizumab
  • avelumab
  • checkpoint inhibitors
  • immunotherapy
  • meta-analysis
  • nivolumab
  • non-small-cell lung cancer
  • pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer : A meta-analysis. / Tartarone, Alfredo; Roviello, Giandomenico; Lerose, Rosa; Roudi, Raheleh; Aieta, Michele; Zoppoli, Pietro.

In: Future Oncology, Vol. 15, No. 20, 01.07.2019, p. 2423-2433.

Research output: Contribution to journalReview article

@article{91fc8ad5f1e648b7ab59adf7139fb398,
title = "Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: A meta-analysis",
abstract = "Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.",
keywords = "atezolizumab, avelumab, checkpoint inhibitors, immunotherapy, meta-analysis, nivolumab, non-small-cell lung cancer, pembrolizumab",
author = "Alfredo Tartarone and Giandomenico Roviello and Rosa Lerose and Raheleh Roudi and Michele Aieta and Pietro Zoppoli",
year = "2019",
month = "7",
day = "1",
doi = "10.2217/fon-2018-0868",
language = "English",
volume = "15",
pages = "2423--2433",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "20",

}

TY - JOUR

T1 - Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer

T2 - A meta-analysis

AU - Tartarone, Alfredo

AU - Roviello, Giandomenico

AU - Lerose, Rosa

AU - Roudi, Raheleh

AU - Aieta, Michele

AU - Zoppoli, Pietro

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.

AB - Aim: At present three immune checkpoint inhibitors (ICIs), two anti-PD-1 (nivolumab and pembrolizumab) and one anti-PD-L1 (atezolizumab) can be used in pretreated non-small-cell lung cancer patients. The aim of this meta-analysis is an indirect comparison between anti-PD-1 and anti-PD-L1 inhibitors. Methods: Seven studies (>4000 patients) were considered. Results: Considering the overall survival ICIs showed very robust efficacy over docetaxel, while in terms of progression-free survival the therapy with ICIs is slightly favored. Anti-PD-1 gives a more significant benefit than anti-PD-L1; however, excluding the KEYNOTE 010 trial that enrolled only PD-L1-positive patients, the subgroup difference remains only in terms of progression-free survival. Conclusion: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.

KW - atezolizumab

KW - avelumab

KW - checkpoint inhibitors

KW - immunotherapy

KW - meta-analysis

KW - nivolumab

KW - non-small-cell lung cancer

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85070081200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070081200&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0868

DO - 10.2217/fon-2018-0868

M3 - Review article

C2 - 31237152

AN - SCOPUS:85070081200

VL - 15

SP - 2423

EP - 2433

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 20

ER -